Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.
bovnews2h
What’s Fueling Exelixis Inc (EXEL) Stock’s 25.88% Gain Above Its 200-Day SMA?
On Wednesday, Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $29.35 which represents a slight increase of $0.85 or 2.98% from the prior close of $28.5. The stock opened at $28.7 and ...
C4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific ...
Exelixis: Navigating Patent Challenges and Future Growth Prospects with a Hold Rating
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
RBC Capital Keeps Their Buy Rating on Exelixis (EXEL)
RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...